Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Share News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.50
Bid: 12.00
Ask: 17.00
Change: 3.60 (31.58%)
Spread: 5.00 (41.667%)
Open: 12.00
High: 15.00
Low: 11.50
Prev. Close: 15.00
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Braemar Says Oil Tankers Wanted For Storage

Thu, 23rd Apr 2020 15:40

(Alliance News) - The following is a round-up of updates by London-listed companies on the impact of the Covid-19 pandemic, issued on Thursday and not separately reported by Alliance News:

----------

Braemar Shipping Services PLC - shipbroking - Sees solid demand in Tankers market due to oversupply of crude oil, leading to a high demand for vessels to be used for oil storage. Order book grows to USD52 million at March 31 from USD50 million February 29. Securities division sees high levels of activity due to market volatility. Logistics division, Cory Brothers, sees relatively strong start to the year driven by both tanker customers and UK exports. Remains positive about the medium-term outlook for the global shipping market. Suspends final dividend payment for the year ended February 28.

----------

Studio Retail Group PLC - home shopping - Underlying pretax profit for year to March 27 from continuing operations likely to be towards the middle of market forecasts. Revenue for the full year in core Studio unit was 3% ahead of prior year. Decides against providing financial guidance for financial 2021. Studio unit traded well ahead of the prior year during the lockdown period, seeing particularly strong demand for ranges such as toys, games, electricals, fitness and garden. Taking a prudent approach towards stock intake for the summer period, particularly on clothing, in order to de-risk the business. Small number of employees at Studio unit furloughed. Non-core Education business furloughs majority of staff due to school closures and sees demand plummet at around 20% to 30% of normal levels. Has net debt of GBP53 million and cash on balance sheet of GBP32 million.

----------

Non-Standard Finance PLC - consumer finance - Lending volumes limited to smaller sized loans to key workers only over the past four weeks. Collections performance robust. Everyday Loans collections above 90% of the comparative pre-lockdown levels in March. Guarantor Loans division collections are running at slightly below 90%. Loans at Home unit collections running at 75% of the expected level. Net cash of GBP38.7 million and gross borrowings of GBP345.0 million as of Tuesday. Has access to additional borrowing facilities totalling GBP185 million. Delays release of 2019 to mid-May.

----------

Dods Group PLC - information, events and publishing - Continues to address the challenges of the virus crisis. Furloughs one-third of workforce in the UK, while remaining staff working remotely. Decides against issuing any forward guidance due to current uncertainty. Appoints Simon Bullock as chief financial officer. Bullock - a chartered management accountant - has over 20 years' experience as a financial director and chief financial officer.

----------

Blackstone/GSO Loan Financing Ltd - investment fund - Medium and long term impact of the virus pandemic remains uncertain. In the short-term, ratings agency downgrades and corporate defaults of companies within investment portfolios may lead to temporary cashflow diversion. Revises dividend policy and now targets 2020 annual dividend of between EUR0.06 and EUR0.07 per share, down from EUR0.10. Declares EUR0.015 per share dividend for the quarter to end-March.

----------

Standard Life Investments Property Income Trust Ltd - commercial property investment - Working closely with tenants to understand their needs during the UK lockdown. Portfolio valuation as at March 31 of GBP458.6 million, down 4.9% from December 31. Loan to value of 24.4% based on March 31 valuation. Cash of GBP5.9 million as of Monday plus GBP47 million in credit facility. Received 66% of rents due as of Monday for second quarter. Rent collection for the period to June 30, and potentially thereafter, to be materially hurt by virus crisis which in turn will reduce future dividends. Confirms intention to pay 1.19 pence per share dividend for the quarter ended March 31. Results for 2019 expected to be released during May.

----------

Smartspace Software PLC - space management software - Taking steps to cut costs and preserve cash including a recruitment freeze, curtailment of all discretionary spend, and office closures. Furloughs 11 staff under UK government's Coronavirus Job Retention Scheme. Withdraws financial guidance for the year ending January 31, 2021. Unable to assess virus impact on financial performance. Had cash of GBP1.9 million as of Monday.

----------

US Solar Fund PLC - solar projects investment - Does not expect Covid-19 to materially impact construction timelines or operating cashflows. More than 55% of the acquired portfolio fully operational and construction of the remainder is progressing to the expected timeline. All debt and tax equity financing required for construction and operations of the acquired portfolio in-place. In a strong position to commence the full 5.5% dividend from first quarter of 2021.

----------

Open Orphan PLC - pharmaceutical services - Subsidiary hVIVO starts testing of an anti-viral for treating Covid-19 on behalf Russian client Nearmedic International Ltd. New drug has both potential anti-viral and anti-inflammatory activity and could reduce both virus infectivity and disease severity. hVIVO will be testing its utility against a panel of viruses to include influenza virus, circulating betacoronavirus and SARS-CoV2.

----------

Trifast PLC - industrial fastenings - Revenue for the year ended March 31 held up well against the prior year. Underlying pretax profit broadly in line with market expectations despite reduced trading levels as a result of reduction in manufacturing volumes across end markets. Decides against declaring dividend for financial 2020. Removes earnings guidance for financial 2021. Making full use of available government backed job retention and wage subsidy schemes. Directors to take a 20% reduction in salaries and fees. Implements a recruitment freeze, a pay-rise deferral, reductions in temporary and contractor headcount and a ban on all non-essential travel.

----------

Trans-Siberian Gold PLC - gold producer - Sees no material impact to production from virus crisis. Dollar-denominated revenue from gold sales remains strong in a supportive gold price environment. Operational costs are rouble-denominated and have fallen due to foreign exchange movements. Revenue for quarter ended March 31 declines to USD9.3 million from USD16.2 million a year ago. First quarter refined gold production down 49% to 6,035 ounces. Gold sales decline 51% to 5,837 ounces. Refined silver output down 28% at 22,205 ounces and sales nil versus 36,329 ounces. Reiterates 2020 gold production guidance of between 38,000 and 42,000 ounces.

----------

Gear4Music PLC - musical instruments - Begins financial 2021 with operational challenges relating to Covid-19. High demand encountered since late March. Appropriately configured to achieve long-term profitable growth. Predicts 9% growth in total sales for year that ended March 31 to GBP120.3 million from GBP109.9 million a year ago. Earnings before interest, tax, depreciation and amortisation of not less than GBP7.0 million versus GBP2.3 million. Cash on hand of GBP7 million at March 31.

----------

SDI Group PLC - scientific and technology products - Continues to operate at all eight sites since UK lockdown began on March 23. To meet market profit expectations for the year ending April 30, with sales of around GBP24 million. Withdraws market guidance for the financial 2021. Cuts salaries and fees of directors by 33% for three months. Furloughs 19% of staff. Current cash in excess of GBP4.5 million, unused debt facilities of GBP600,000, and bank debt of GBP8.9 million.

----------

Amryt Pharma PLC - rare disease treatment - Halts further enrolment to global phase 3 clinical study in Epidermolysis Bullosa, a rare genetic condition resulting in easy blistering of the skin and mucous membranes. Shortly after the last patient completes the end of the double-blind treatment period, the study data will be cleaned and the database locked. Top line data from study expected in late third quarter or early fourth quarter of 2020.

----------

Collagen Solutions PLC - biomaterials and regenerative medicines - Revenue for year to March-end expected to fall 3.3% year-on-year to GBP4.0 million. Experienced Covid-19 impact to the business in March which have hurt full year revenue and are expected to continue to damage trading for the near future. Facing challenges from the virus outbreak in production, logistics and customers. Pursuing additional funding sources including various governments' Covid-19 loans and grants. Board and senior executives including chief executive officer taking 25% pay cut for up to six months. Cash balances at March-end of GBP2.1 million.

----------

Synectics PLC - security and surveillance systems - All business units currently operating, but at significantly reduced levels of activity in every sector and geography. Financial guidance for year ending November 30 remains suspended. Withdrawing resolution for final dividend at annual general meeting. Reducing temporarily salaries and fees for the board and senior management team. Utilising the UK government's Job Retention Scheme, with 30% of UK workforce furloughed. Applying for support, as appropriate, from government schemes in the US, Germany and Singapore. Suspending all discretionary spending, recruitment and capital expenditure. Net cash of GBP3.3 million as of Monday, with confirmed loan facilities of GBP5.0 million.

----------

Kavango Resources PLC - explorer of mineral deposits in Botswana - Minimal disruption so far to the company's operations with recent work focused on analysis and modelling of all data collected over the last 18 months. Constructing a 3D underground map of the northern part of the Kalahari Suture zone. Assessing other prospecting licences at Kalahari copper belt. Seeking a joint venture partner for the Ditau project.

----------

Braveheart Investment Group PLC - fund management and investment - Majority owned Pharm 2 Farm Ltd manufacturing medical grade alcohol hand sanitiser gel. To increase production to 2,000 litres per day by the end of May. Investee Kirkstall Ltd working with Animal Free Research UK to implement new and existing techniques to replace the use of animal in trials and research.

----------

Berkeley Energia Ltd - uranium producer - Focusing on progressing the approvals required to commence construction of the Salamanca mine in Spain and bring it into production. Sees 30% year-to-date jump in uranium spot price to USD32.50 per pound amid uncertainty surrounding Covid-19 impact on the nuclear fuel supply chain.

----------

Cadence Minerals PLC - minerals project investor - No effect of virus outbreak on lithium and tin project in Cinovec, Czech Republic. Restrictions on travel and meetings not expected to have any impact for the foreseeable future on the project. European Metals Holdings Ltd investors have approved EUR29.1 million investment in Cinovec project.

----------

Redx Pharma PLC - drug discovery - Halts recruitment to its phase 1/2a clinical trial of RXC004, an oral porcupine inhibitor, to prioritise resources for the UK's National Health Service. Majority of operations in the discovery phase, preclinical phase, and in ongoing research collaborations continuing to plan. Continuing long-term funding discussion with US healthcare firm Redmile Group LLC.

----------

Great Western Mining Corp PLC - minerals exploration in US - Introduces cost saving measures, including agreements with directors and staff to defer 30% of their salaries. Remains in a good cash position and looks forward to restarting activities in the US state of Nevada as soon as circumstances permit.

----------

JPMorgan Claverhouse Investment Trust PLC - investment fund - Directors to reduce fees by 20% due to coronavirus events and the recent fall in assets. The reduction will take effect from start of April 2020 and will continue until June-end.

----------

TP Group PLC - secure communication and software systems - Auditors RSM UK Audit LLP unable to meet agreed timetable to formally report 2019 results. Expects substantial growth in both revenue and adjusted operating profit for 2019, with a significant strengthening of the order book. Seeking clarity from RSM with regards to the timetable for publishing results.

----------

By Tapan Panchal; tapanpanchal@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
13 Dec 2022 15:53

UK earnings, trading statements calendar - next 7 days

Wednesday 14 December 
Cohort PLCHalf Year Results
CyanConnode Holdings PLCHalf Year Results
Foresight Sustainable Forestry Co PLCFull Year Results
IntegraFin Holdings PLCFull Year Results
SThree PLCTrading Statement
Tui AGFull Year Results
Watches of Switzerland Group PLCHalf Year Results
Thursday 15 December 
Biffa PLCHalf Year Results
C4X Discovery Holdings PLCFull Year Results
Currys PLCHalf Year Results
Libertine Holdings PLCHalf Year Results
RWS Holdings PLCFull Year Results
Serco Group PLCTrading Statement
Friday 16 December 
Gore Street Energy Storage Fund PLCHalf Year Results
Hollywood Bowl Group PLCFull Year Results
Monday 19 December 
Thruvision Group PLCHalf Year Results
Tuesday 20 December 
Jersey Electricity PLCFull Year Results
Petrofac LtdTrading Statement
Redx Pharma PLCFull Year Results
  
Copyright 2022 Alliance News Ltd. All Rights Reserved.

Read more
11 Nov 2022 15:24

TRADING UPDATES: De La Rue defends chair; Resolute Mining fundraise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
11 Oct 2022 14:51

TRADING UPDATES: Scirocco repays loan; Vp says rail strikes slow works

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
5 Oct 2022 22:06

TRADING UPDATES: Blencowe Resources sees potential interest from China

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
5 Aug 2022 13:58

Redx Pharma staff sell 1.5 million shares via accelerated bookbuild

(Alliance News) - Redx Pharma PLC on Friday confirmed that Chief Scientific Officer Richard Armer and other current and former employees have sold a total of 1.5 million shares at 59 pence each via an accelerated bookbuild.

Read more
3 Aug 2022 17:57

IN BRIEF: Redx Pharma employees to sell at least GBP605,120 in shares

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Chief Scientific Officer Richard Armer and other current and former employees look to sell 1.5 million shares at a minimum price of 59 pence each via an accelerated bookbuild, which is 11% discount to Tuesday's closing price of 66.50p.

Read more
27 Jun 2022 16:01

IN BRIEF: Redx Pharma reports "encouraging" fibrosis treatment data

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes encouraging preclinical data for the potential of its Porcupine and ROCK inhibitors to tackle cancer-associated fibrosis. Further data supported the ROCK inhibitor as a potential treatment for fibrostenotic Crohn's disease.

Read more
23 Jun 2022 11:29

IN BRIEF: Redx Pharma narrows half-year loss as pipeline progresses

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - In the half year ended March 31, pretax loss narrows to GBP9.7 million from GBP12.7 million year-on-year. Revenue multiplies to GBP8.4 million from GBP2.1million. Reports strong progress across its pipeline, especially its lead oncology asset RXC004 moving into phase II clinical trials, and its lead fibrosis asset, RXC007, reporting "encouraging" phase I safety data. Says its Rock inhibitor RXC008 has the potential to become a first-in-class treatment for fibrostenotic Crohn's disease, and is likely to be ready to enter the clinic by the end of next year.

Read more
16 Jun 2022 16:05

UK earnings, trading statements calendar - next 7 days

Friday 17 June 
Tesco PLCQ1 Results
Monday 20 June 
Associated British Foods PLCQ3 Results
SysGroup PLCFull Year Results
SThree PLCTrading Statement
Tuesday 21 June 
DS Smith PLCFull Year Results
Gear4Music PLCFull Year Results
Monks Investment Trust PLCFull Year Results
Record PLCFull Year Results
Safestore Holdings PLCHalf Year Results
Telecom Plus PLCFull Year Results
Wednesday 22 June 
Berkeley Group Holdings PLCFull Year Results
Liontrust Asset Management PLCFull Year Results
Micro Focus International PLCHalf Year Results
Thursday 23 June 
DeepVerge PLCFull Year Results
First Property Group PLCFull Year Results
Manolete Partners PLCFull Year Results
Naked Wines PLCFull Year Results
Oxford Metrics PLCHalf Year Results
Redx Pharma PLCHalf Year Results
Serco Group PLCTrading Statement
Volex PLCFull Year Results
XPS Pensions Group PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
15 Jun 2022 10:24

Redx Pharma rises on FDA clearance for solid tumour treatment JZP815

(Alliance News) - Redx Pharma PLC on Wednesday said the US Food & Drug Administration has cleared the investigational new drug application for JZP815, a pan-RAF inhibitor for the treatment of solid tumours and haematological malignancies.

Read more
19 May 2022 18:55

TRADING UPDATES: Knights tips revenue hike; Gym Group eyes growth

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 May 2022 19:37

IN BRIEF: Redx Pharma to raise GBP30 million to fund pipelines

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Proposes to raise GBP30 million through a placing to institutional investors of shares at a price of 59 pence each.

Read more
8 Apr 2022 19:41

IN BRIEF: Redx Pharma notes "encouraging" RXC004 data in cancer

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes "encouraging" preclincal data for RXC004 as a targeted therapy for Wnt-ligand driven cancer.

Read more
5 Apr 2022 21:39

TRADING UPDATES: Alpha FX restarts relationship; Atalaya resources up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
30 Mar 2022 11:05

IN BRIEF: Redx Pharma to start new Crohn's disease study in late 2023

Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Announces end of 2023 as start of phase 1 studies for its Crohn's disease clinical development candidate RXC008. The inhibitor is designed to act exclusively in the gastrointestinal tract at the site of fibrosis in Crohn's disease patients. Up to 50% of patients with Crohn's disease can develop significant fibrosis, the company says, citing a 2013 study published by the National Center for Biotechnology Information based in Bethesda, Maryland, United States.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.